[Form 4] Concentrix Corp Insider Trading Activity

Rhea-AI Filing Summary

Christopher A. Caldwell, President and CEO and Director of Concentrix Corp (CNXC), reported a sale of common stock on 10/07/2025. The filing shows 390 shares were sold at $47.76, leaving Mr. Caldwell with 304,345 shares held directly after the transaction. The Form 4 was signed by an attorney-in-fact on 10/09/2025. No options or derivative transactions were reported.

Positive

• Executive retains substantial direct ownership of 304,345 shares after the sale
• Reported transaction is small (390 shares), suggesting it is unlikely to materially alter insider alignment with shareholders

Negative

• Insider sale occurred, which investors sometimes view as a neutral-to-negative signal depending on context
• No explicit 10b5-1 plan checkbox was indicated in the provided filing text

Insights

Corporate Governance Analyst

Insider sale was small relative to total holdings and consistent with routine liquidity.

The report documents a discrete sale of 390 shares at $47.76 by the company's President and CEO on 10/07/2025, leaving 304,345 shares held directly. This level of disposition represents a very small percentage of the reported post-transaction holdings.

The primary dependency is whether the sale was part of a pre-established plan; no Rule 10b5-1 plan checkbox is marked in the filing text provided. Monitor any subsequent Form 4s within the next several weeks for patterns that could indicate ongoing trading.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Caldwell Christopher A

(Last) (First) (Middle)

39899 BALENTINE DRIVE

SUITE 235

(Street)

NEWARK CA 94560

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Concentrix Corp [ CNXC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
10/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/07/2025		F		390	D	$47.76	304,345	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Andrew A. Farwig, Attorney-in-Fact	10/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Concentrix (CNXC) insider Christopher Caldwell report on the Form 4?

The Form 4 reports that Christopher A. Caldwell sold 390 common shares at $47.76 on 10/07/2025, with 304,345 shares held directly after the sale.

How much stock does Christopher Caldwell own after the reported transaction?

He holds 304,345 shares of Concentrix common stock following the transaction reported on 10/07/2025.

Was the Form 4 signed and when was it filed?

The filing bears a signature by an attorney-in-fact on 10/09/2025, as indicated in the document.

Did the filing show any option or derivative transactions for Mr. Caldwell?

No. Table II for derivative securities shows no derivative transactions were reported in the supplied content.

Is there an indication the sale was part of a Rule 10b5-1 trading plan?

The provided text does not indicate a checked 10b5-1 plan box; therefore no explicit 10b5-1 plan is shown in the excerpt.